What is it about?
Patients with type 2 diabetes have higher risk of kidney disease. We developed a risk score that can help identify patients with type 2 diabetes that are at higher risk of kidney disease progression and who experience greater magnitude of effect from SGLT2 inhibitors.
Featured Image
Read the Original
This page is a summary of: Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes, Diabetes Care, August 2023, American Diabetes Association,
DOI: 10.2337/dc23-0492.
You can read the full text:
Contributors
The following have contributed to this page
